The AMCARE consortium will develop a novel suite of bio-interactive Hyaluronan (HA) based materials and on-demand drug release systems to Human Mesenchymal Stem Cells (MSC)-Derived Cardiopoietic Cells in a protected fashion to the harsh environment of the post-MI ischemic myocardium (Figure 1). The novel formulations and delivery methods proposed, which optimise cardiopoietic cell therapy by coupling smart biomaterials with minimally-invasive surgical devices, help post-MI patients in restoring cardiac function by targeting for repair the underlying myocardium damage. This novel treatment for post-MI patients can potentially decrease morbidity and mortality, improving long-term healthcare of EU citizens by offering a new therapeutic modality to treat acute MI patients in the future. Furthermore, there is enormous commercial scope for our novel biomaterial technologies and devices, whereby we propose to harness the potential of regenerative medicine in Europe and translate this to future industrial success.
AMCARE Approach Overview: Three distinct but Complimentary Phases
Advanced Therapeutics - Cardiac Progenitor Cells (CPCs):
A major hurdle to successful clinical translation of cardiac cell therapy is poor cell survival, engraftment and retention in the infarct damaged heart. The AMCARE consortium hypothesise that enhanced efficacy can be achieved by increasing the retention of stem cells in the damaged myocardium or heart tissue following delivery, reducing potentially the effective dose, increasing the safety by reducing the risk of unwanted side effects as well decreasing the costs of cell therapy treatment.